Immediate Impact
1 by Nobel laureates 52 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
2025 Standout
Works of Jaimie Heldstab being referenced
Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jaimie Heldstab | 35 | 33 | 23 | 6 | 60 | |
| Eric Bernstein | 30 | 23 | 21 | 8 | 81 | |
| Mohamed Elfagieh | 28 | 25 | 16 | 8 | 60 | |
| Miriam M. Yeung | 29 | 32 | 38 | 6 | 88 | |
| Nitin Rohatgi | 27 | 19 | 23 | 7 | 58 | |
| Yuexin Chen | 29 | 63 | 17 | 7 | 83 | |
| Erik Tilch | 40 | 37 | 19 | 5 | 73 | |
| Alana S. Weinstein | 18 | 36 | 29 | 8 | 67 | |
| Jim Cregg | 40 | 58 | 9 | 7 | 77 | |
| Chunxin Qin | 31 | 56 | 22 | 7 | 88 | |
| Suzanne Allan | 29 | 38 | 16 | 4 | 62 |
All Works
Loading papers...